The Purpose-Built Infusion RCM Platform as a Platform Acquisition Prerequisite

An infusion-only RCM platform for buy-and-bill practices needs drug coding, authorization tracking, contract reconciliation, and collections built around infusion reimbursement. For private equity and strategic buyers, that infrastructure is an acquisition prerequisite because reliable reported revenue and scalable operations depend on it. The test is not the software label, but the financial evidence the business can produce before close.

Why private equity is betting on infusion platforms right now

Lasting demand for infusion gives private equity a reason to bring practices together. Bourne Partners’ December 2025 infusion report notes that nearly half of all new molecular entity approvals since January 2021 have been for drugs requiring intravenous, intramuscular, or subcutaneous administration. The pharmaceutical pipeline is reinforcing the investment case. Meanwhile, the Inflation Reduction Act’s “pill penalty” shields biologics from Medicare price negotiation for longer than small molecules, directing capital and innovation toward drugs that route patients to infusion centers.

A fragmented market gives buyers room to consolidate. Independently owned practices make up most of the market, giving buyers room to buy sites, add the systems needed to manage them, and build multi-site businesses. But the investment thesis assumes that acquired financial performance can be repeated across a larger operation. Consolidation is only as good as the financial infrastructure underneath it.

Why RCM infrastructure is now a diligence question, not just an operations question

FTI Consulting identifies revenue cycle management as one of four critical value levers in infusion, together with analytics and data, vendor negotiations, and specialty pharmacy insurance benefits. That places RCM within the acquisition case. Buyers are buying the ability to collect revenue again and again. Reported financials alone cannot prove that ability when the systems behind them have weak controls over drug pricing, payer rules, documentation, or administration billing.

The practical risk runs in two directions. A practice using general-purpose billing infrastructure may collect less than its contracts allow while presenting accounts receivable, or AR, that look cleaner than they are. Unidentified underpayments suppress collections, while unresolved denials weaken the value of outstanding balances. A buyer who accepts those figures without examining the underlying workflows may price in capability that does not exist. Conversely, sellers with documented control over these risks can defend their financials and negotiate from a stronger position.

What billing software do infusion centers need for buy-and-bill reimbursement?

Most infusion drugs use a HCPCS J-code, but the code is only the starting point. Drug units must equal the dose that was administered divided by the J-code unit size. Dose changes, split vials, and rounding create opportunities for error. NDC reporting also depends on the payer, with Medicaid and many commercial payers requiring it. Newly approved drugs that lack permanent J-codes need unlisted/NOC codes such as J3490, J3590, and J9999, along with extensive supporting documentation and closer review by the payer.

Administration billing adds another set of dependencies. Infusion sequencing and drug administration hierarchy rules mean one coding error can invalidate an entire claim, including thousands of dollars in drug charges. Buy-and-bill makes that failure costly because the practice has already taken on the acquisition risk. Average Sales Price, or ASP, reimbursement can lag rising acquisition costs, compressing the spread even before a claim is denied or delayed. The software must also distinguish white-bagging administration-only encounters from buy-and-bill encounters within the same practice, rather than treating both as the same billing workflow.

How prior authorization failures seed revenue loss before a claim is ever submitted

Authorization errors appear in diligence as denials and gaps between scheduled treatment and billable visits. The loss starts before claim submission. An authorization for the wrong site of care, or a drug substitution without a new authorization, can produce a denial that tightened retro-authorization policies make difficult to recover. Denied authorization requests also delay treatment, so the practice loses revenue from visits that never take place. A review of only submitted claims therefore misses some of the money at risk.

Recurring treatment compounds the problem because authorization is not a one-time clearance. Approvals expire, authorized visits run out, and ongoing treatment requires reauthorization. A lapse mid-cycle can be harder to appeal than an error caught before the first infusion. The recommended control is a standing report showing active authorizations, remaining visits, days until expiration, and dollar value at risk, sorted by proximity to expiration. Without that prospective view, repeated expiration denials point to a monitoring failure rather than an isolated mistake, and the buyer inherits preventable write-offs.

Denial patterns that indicate structural RCM failure versus recoverable process gaps

A high denial rate does not identify its cause. In oncology infusion, hierarchy errors, authorization failures for high-cost drugs, and documentation shortfalls require different responses. An aggregate denial bucket hides those differences. Buyers need reporting by denial reason, segmented by payer, drug category, and site. That breakdown shows whether a business has a coding problem it knows how to fix or cannot tell why its claims fail.

Payer-specific reporting is equally important because published coverage policies and actual authorization decisions can differ across health plans, therapies, and geographies. Without that distinction, a practice can mistake a payer policy gap for missing documentation. Trends then show whether the response is working. Appeal overturn rates reveal whether denial management recovers value, while root-cause reporting separates authorization, coding, documentation, and timely-filing failures. A correctable process gap has an identifiable cause and a measurable response. The inability to produce that evidence is itself a structural defect, and buyers should price the uncertainty rather than assume that a high-level denial total tells the full story.

Underpayments hidden in remittances and why they are permanently lost without line-level reconciliation

A paid claim can still leave the practice short of what the contract says it is owed. Many practices bill from fee schedules that do not match their actual contracted rates, while payers post differences as adjustments. Those adjustments can go unchallenged without an automated variance check. Unlike a denial, an underpayment may not present itself as unfinished work. It becomes a permanent loss when no one compares the payment with the amount contractually due.

The diligence evidence is a payer performance scorecard showing expected versus actual reimbursement by payer and site, supported by real-time, line-level reconciliation. Without a contract variance report, the buyer cannot tell whether the practice collected what its contracts say it is owed. That uncertainty affects both the estimate of sustainable revenue after close and the recovery of old balances. Because infusion visits can bring thousands of dollars in charges, mostly for drugs, even a small payment shortfall adds up across a multi-site business.

What AR aging reveals about an infusion platform's collection discipline

AR aging shows the effects of earlier failures. Old balances can come from expired authorizations, incorrect coding, unresolved denials, or claims that collection staff did not reach in time. High ninety-day AR and high write-offs should therefore prompt the buyer to look back through the revenue cycle for the point when those balances first became hard to collect.

Age also changes what an outstanding balance is worth. The longer claims stay unresolved, the less likely they are to be paid, and collection work after close cannot recover all the money lost on aging high-dollar biologic claims. That makes queue design part of the diligence review. Infusion AR should be prioritized by dollar value, age, payer, denial category, and proximity to the appeal deadline. A queue that treats every balance alike systematically under-recovers on the most valuable claims.

How multi-site consolidation exposes RCM infrastructure that worked at single-site scale

A single-site billing operation is not automatically a platform. Many independent practices were built to run one location and lack cross-site analytics, a standard way to report denials, or a central team to manage authorizations. A buyer may therefore inherit several separate billing operations with limited capacity to expand. The weakness becomes visible when the acquired sites must be compared and managed together.

For example, denial rates and root causes may differ by location even though no one has ever compared them side by side. That conceals both useful practices and poor performance. Site-specific, undocumented authorization workflows then make standardization slow and error-prone, while different contract terms require centralized reconciliation to expose underpayments across the business. Meaningful AR aging rollups require a common reporting layer, an operational requirement as well as a reporting one. Without cross-site visibility, the buyer can struggle to locate performance problems until declining collections expose them, while the work required to standardize each acquired operation compounds.

What a purpose-built infusion RCM infrastructure looks like under diligence

Purpose-built infrastructure makes the earlier risks visible and manageable. Its authorization workflow begins at first patient contact and is integrated into scheduling, with a live view of expiration proximity and dollar value at risk. Its billing workflow includes J-code and NDC logic, dose-unit calculations, and handling for unlisted/NOC codes. These capabilities must appear in the working process. A description of what software could support is not the same as evidence of what the practice controls.

CARC-code-level denial trends should be available by payer, drug category, and site, together with appeal overturn rates. A payer scorecard should reconcile contracted rates against actual remittances at the line level in real time. Dollar-weighted AR queues and cross-site comparisons then show whether all the acquired locations follow the same discipline in collecting what they are owed.

Software alone is not the whole operating model. Automation handles large volumes of work in a consistent way, while experienced infusion billing operators handle authorization edge cases, payer-specific denial patterns, and appeal decisions that rules engines cannot resolve. Together, those capabilities allow a seller to demonstrate that revenue is defensible, AR is collectible, and collection performance can be repeated as the business grows. The infrastructure itself supports the clinical operation and becomes part of the asset being acquired.

What buyers and operators should do before a transaction closes

For buyers, the lesson is to make RCM infrastructure a distinct diligence workstream. Request at least the prior year of denial reports broken down by reason, payer, and site, with trends. Pull dollar-stratified AR aging and compare write-off rates with HFMA benchmarks, then trace high aging back to what caused it. The financial statements will not expose every missing control. Authorization review should document where approval work begins in intake, how expiration is tracked, and how authorization-to-billing alignment is verified before submission.

If the target relies on general-purpose RCM or internal health system billing staff, buyers should build remediation cost and time into the acquisition model. The transition can take longer than expected. Pricing the work before close is different from inheriting it afterward, especially when the planned consolidation depends on common reporting and repeatable collections.

For operators preparing to sell, the corresponding action is to build defensible infrastructure well before diligence begins. Clean denial trends, a payer performance scorecard, and authorization-integrated scheduling provide documented financial strength. Moving to purpose-built infusion RCM therefore improves billing and is an investment in what the business is worth. An end-to-end model should connect benefits verification and prior authorization through denial management, payment posting, and AR, combining software with experienced operators.